Protective role of cannabinoid CB 1 receptors and vascular effects of chronic administration of FAAH inhibitor URB597 in DOCA-salt hypertensive rats

Activation of CB1receptors by 2-arachidonoylglycerol attenuates vasoconstriction induced by U46619 and angiotensin II in human and rat pulmonary arteries

“…Sections (3 sections of each lung from 3 patients and rats) were cut to be 4 m in thickness (by a Leica 2025 rotating microtome). The EnVision method was used according to the protocol of Baranowska-Kuczko et al (3), using an antibody against the CB1 receptor (1:1,000; rabbit anti-CB1). The specificity of the antibody for the CB 1 receptor was examined using both a negative control, in which the antibodies were replaced by normal rabbit serum at the respective dilution (no staining), and a positive control, which was prepared from the rat brain.…”

Endocannabinoids modulate Gq/11 protein-coupled receptor agonist-induced vasoconstriction via a negative feedback mechanism

“…Rat uterine artery [8] Human kidney endothelial cells [52] Human umbilical vein [58] Mouse pulmonary artery [37] Human pulmonary cell line [37] Skeletal muscle arteries [59] Bovine coronary artery [60] Human pulmonary artery [11] Rat aorta [6] Small mesenteric artery [6] Mouse cerebral artery (microcirculation) [61] Vascular level 2-AG Bovine coronary artery [24] Rat aorta [23] Human umbilical vein [58] N.A. Rat middle cerebral artery [26] Rat mesenteric artery [62] Mice aorta [63]…”

“…Therefore, in various forms of hypertension, the eCB system becomes tonically active. This occurs by enhancing the vasorelaxant responses to eCBs, changes in plasma eCB concentration or alterations in the vascular expression of eCB system components, including up‐regulation of CB 1 receptors . It is worth mentioning that more research concerns the possible role of the eCB system in cardiovascular regulation in hypertension …”

“…This occurs by enhancing the vasorelaxant responses to eCBs, changes in plasma eCB concentration or alterations in the vascular expression of eCB system components, including up-regulation of CB 1 receptors. [3][4][5][6][7] It is worth mentioning that more research concerns the possible role of the eCB system in cardiovascular regulation in hypertension. [3,6,8] Cannabinoid signalling through the CB 1 -sensitive pathway can cause vasorelaxation via activation of nitric oxide synthase, increase in cyclic guanosine monophosphate and opening of potassium channels which causes membrane hyperpolarization, [5,9] see also Table 1.…”

“…[3][4][5][6][7] It is worth mentioning that more research concerns the possible role of the eCB system in cardiovascular regulation in hypertension. [3,6,8] Cannabinoid signalling through the CB 1 -sensitive pathway can cause vasorelaxation via activation of nitric oxide synthase, increase in cyclic guanosine monophosphate and opening of potassium channels which causes membrane hyperpolarization, [5,9] see also Table 1. In addition, the metabolism of eCBs into arachidonic acid, and other vasodilator eicosanoids, comprises their other vasorelaxant property (but not CB 1 receptor-dependent); [4,10,11] however, we will not develop this topic in this review.…”